ArticleNutrients2017
A Novel Prebiotic Blend Product Prevents Irritable Bowel Syndrome in Mice by Improving Gut Microbiota and Modulating Immune Response.
Article in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Pharmacological treatments for patients with irritable bowel syndrome: An umbrella review of systematic reviews and meta-analyses.Medicine · 2019Pooled it
- Postbiotics as Next Generation Biotherapeutics Targeting the Gut-Immune-Metabolic Axis: An Integrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach.Nutrients · 2025Review
- Article
- PPARγ activation attenuates neonatal CRD-induced visceral pain sensitization and anxiety in male rats by alleviating oxidative stress.BMC gastroenterology · 2025Article
- Article
- Review
- Gut pathobiome mediates behavioral and developmental disorders in biotoxin-exposed amphibians.Environmental science and ecotechnology · 2024Article
- Gut microbiome biomarkers in adolescent obesity: a regional study.Health information science and systems · 2023Article
- Factors Influencing Microbiota in Modulating Vaccine Immune Response: A Long Way to Go.Vaccines · 2023Review
- Circulating LPS from gut microbiota leverages stenosis-induced deep vein thrombosis in mice.Thrombosis journal · 2023Article
- Bioactives and their roles in bone metabolism of osteoarthritis: evidence and mechanisms on gut-bone axis.Frontiers in immunology · 2023Review
- Anthocyanins: Metabolic Digestion, Bioavailability, Therapeutic Effects, Current Pharmaceutical/Industrial Use, and Innovation Potential.Antioxidants (Basel, Switzerland) · 2022Review
- Review
- Celiac Disease and Possible Dietary Interventions: From Enzymes and Probiotics to Postbiotics and Viruses.International journal of molecular sciences · 2022Review
- Oligosaccharide equine feed supplement, Immulix, has minor impact on vaccine responses in mice.Scientific reports · 2022Article
- Galactooligosaccharide Treatment Alleviates DSS-Induced Colonic Inflammation in Caco-2 Cell Model.Frontiers in nutrition · 2022Article
- Effects of Chang-Kang-Fang Formula on the Microbiota-Gut-Brain Axis in Rats With Irritable Bowel Syndrome.Frontiers in pharmacology · 2022Article
- The Impact of Weaning Stress on Gut Health and the Mechanistic Aspects of Several Feed Additives Contributing to Improved Gut Health Function in Weanling Piglets-A Review.Animals : an open access journal from MDPI · 2021Review
- Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder yet it still lacks effective prevention therapies. The aim of this study is to determine whether a novel prebiotic blend (PB) composed of fructo-oligosaccharide (FOS), galactooligosaccharide (GOS), inulin and anthocyanins could be effective in preventing the development of IBS. We explored the possible mechanisms both in animal and in cells. Post-infectious IBS models in C57BL/6 mice were established and were pretreated with the PB, PB and probiotic strains 8 weeks in advance of infection. Eight weeks after infection, intestinal tissues were collected for assessing histomorphology, visceral sensitivity, barrier function, pro-inflammatory cytokines expression and proteomics analysis. Fecal samples were also collected for microbiota analysis. The pro-inflammatory cytokines expression in Caco-2 cells were evaluated after co-incubation with PB and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.